Brandsma, Maynard; Sternberg, Thomas H.; Davis, John H.
March 1970
Angiology;Mar1970, Vol. 21 Issue 3, p172
Academic Journal
In the past the treatment of SLE has varied a great deal without much result. Antimalarial drugs have been used with mediocre results. Salicylates can be helpful in controlling muscle pains. ACTH and steroids have been most effective in controlling the inflammatory manifestations of SLE. In the case reported here, chloroquine had no result whatsoever and prednisone did not seem to improve the condition. Because her overall status was so desperate, it was felt justified to use an experimental drug such as dimethyl sulfoxide, first of all to increase the action of fluocinolone, as DMSO acts as a solvent and can be used by applying medication percutaneously with a subsequent absorption in the blood stream. When the eye symptoms developed we could not be sure if they were due to steroids or the DMSO, but they had all the earmarks of steroid toxicity as has been reported in cases developing a pseudo-tumor syndrome. For that reason we decided to continue the DMSO without further use of steroids and the patient improved rapidly. At the time of this writing, which is 3 years after all treatment was discontinued, the patient actually has no signs or symptoms of SLE and we therefore felt that she is without question in a complete remission. None of us has ever seen such as advanced case of SLE in a young woman with such a long-lasting remission. We now have two possibilities. The patient went into a remission because of the huge dosage of steroids used orally as well as percutaneously, or she improved because of the use of DMSO. Because massive steroid therapy has rarely if ever produced a complete remission such as this, we feel that a DMSO action cannot be discounted. After we terminated the treatment, the Food and Drug Administration of the United States decided to withdraw this drug for experimental use because of eye disturbances reported in animals. We were therefore unable to duplicate this in other cases but are reporting this, first of all for the rather unusual features in this case, together with the almost disastrous result of steroid treatment, and with the hope that others will have an opportunity to use dimethyl sulfoxide on these cases and see if our results can be duplicated. At the time of this writing, the patient has been completely well without symptoms and with a negative antinuclear antibody test and negative LE test and LE preparation.


Related Articles

  • Clinical: Systemic lupus erythematosus. Lee, Jeffrey; Ellis, Spencer // GP: General Practitioner;10/5/2007, p18 

    The article presents information on symptoms and management of systemic lupus erythematosus (SLE). SLE is a chronic autoimmune inflammatory disorder that can affect almost any organ, often resulting in diverse clinical features. Non-specific symptoms of the disease are common, including fever,...

  • Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Gottschalk, Timothy A.; Tsantikos, Evelyn; Hibbs, Margaret L. // Frontiers in Immunology;Oct2015, Vol. 6, p1 

    Systemic lupus erythematosus (SLE, lupus) is a highly complex and heterogeneous autoimmune disease that most often afflicts women in their child-bearing years. It is characterized by circulating self-reactive antibodies that deposit in tissues, including skin, kidneys, and brain, and the ensuing...

  • Therapeutic response and long-term follow-up in a systemic lupus erythematosus patient presenting with Kikuchi's disease. Vil�, L.; Mayor, A.; Silvestrini, I. // Lupus;Feb2001, Vol. 10 Issue 2, p126 

    Kikuchi's disease (KD) can occur in association with systemic lupus erythematosus (SLE). The treatment of concomitant diseases, however, is unclear. We describe a case of a 45-y-old man who presented with generalized histiocytic necrotizing lymphadenitis, fever, malaise and weight loss. Ten...

  • Reply to the letter 'Mean platelet volume as a surrogate marker of inflammation in systemic lupus erythematosus'. Yavuz, Sevgi; Ece, Aydın // Clinical Rheumatology;Nov2014, Vol. 33 Issue 11, p1693 

    A letter to the editor is presented in response to the article "Mean Platelet Volume As a Surrogate Marker of Inflammation in Systemic Lupus Erythematosus" by Sevgi Yavuz and Aydm Ece, which appeared in a previous issue of the journal.

  • Früher Lupus erythematosus. Fischer-Betz, R.; Schneider, M. // Zeitschrift für Rheumatologie;Dec2013, Vol. 72 Issue 10, p948 

    Early diagnosis of systemic lupus erythematosus (SLE) is a challenge even for experienced rheumatologists due to the heterogeneous appearance of the disease. The initial phase of SLE often comprises unspecific general symptoms and only few characteristic clinical and laboratory abnormalities in...

  • Azathioprine/cyclophosphamide/glucocorticoids.  // Reactions Weekly;8/1/2013, Issue 1463, p12 

    The article presents a case study of a woman, with systemic lupus erythematosus (SLE), who developed acute meningoencephalitis after treatment with prednisone, methylprednisolone, azathioprine, and cyclophosphamide.

  • Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Tam, L.S.; Li, E.K.; Lam, C.W.K.; Tomlinson, B. // Lupus;2000, Vol. 9 Issue 6, p413 

    Objective: To investigate the effects of hydroxychloroquine (HCQ) in Chinese patients with systemic lupus erythematosus who were either on a low dose of prednisone or not on prednisone. Methods: 65 consecutive Chinese lupus patients without features of nephritis underwent assessment of the...

  • Methotrexate therapy in systemic lupus erythematosus. Sato, E. // Lupus;Mar2001, Vol. 10 Issue 3, p162 

    There are 12 non-controlled and only two controlled studies using methotrexate (MTX) in a total of 207 SLE patients in the literature. The majority of these studies evaluated mainly cutaneous and/or articular involvement and attained good results. Two studies evaluated a small number of patients...

  • Azathioprine therapy for patients with systemic lupus erythematosus. Abu-Shakra, M.; Shoenfeld, Y. // Lupus;Mar2001, Vol. 10 Issue 3, p152 

    Azathioprine is the only purine analog that is widely used for the management of systemic lupus erythematosus (SLE). For SLE patients without renal involvement, it is given to those patients who require a maintenance dose of 15 mg or higher of prednisone and for those who experience recurrent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics